Here's what I'll say, because I appreciate that point of view on the simplicity and long term benefit of no royalties - even as late as March Gerald was still touting 60/40 and striking this deal in march rather than Jan greatly benefits NLC because of our stock decline.

I'll be frank - this 10-k doesn't read well to me, especially knowing that revenue for the most part evaporated a few weeks later. Q1 won't be a great number - I'm guessing $2.5M, and our cash sucks. I agree with a poster from another board - it's taking a lot of $ to make $ and we are definitely taking risks where we invest in growth. I'm also not positive there's no royalty.

It sucks that we're having to fight in the courts to get back what amounts to 25% of our annual revenue from people who haven't paid us for services. I think we're in the clear on boneheaded financial deals but dang those financings in early 2021 and late 2020 have just murdered us. Getting cash settlements on those things could be HUGE for us. I just don't believe in Tollovid to keep the lights, much less power a major diagnostic trial.

As an AMBS investor, I'm also concerned they'll bounce GC, who hasn't exactly protected our stake, but someone new will have absolutely no incentive to protect it from dilution. He's done a lot of good, but it doesn't outweigh the bad yet again, at least yet.